Histogen Revenue and Competitors
Estimated Revenue & Valuation
- Histogen's estimated annual revenue is currently $6M per year. 0
- Histogen's total funding is $76.8M.
Employee Data
- 00
Histogen's People
| Name | Title | Email/Phone |
|---|
Histogen Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5.4M | 70 | -8% | $53M | N/A |
#2 | $32.4M | 167 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.8M | 18 | 13% | N/A | N/A |
#5 | $0.8M | 5 | -50% | N/A | N/A |
#6 | $0.8M | 10 | 0% | N/A | N/A |
#7 | $14M | 90 | -12% | N/A | N/A |
#8 | $0.4M | 336 | 10% | $236.7M | N/A |
#9 | $4.8M | 62 | -74% | $160M | N/A |
#10 | $3.7M | 24 | -8% | N/A | N/A |
What Is Histogen?
Histogen, Inc. is a regenerative medicine company based on naturally-produced products from newborn fibroblasts grown in a proprietary bioreactor that mimics the embryonic environment. Histogen has developed a rich product portfolio from one core technology process that fulfills market needs without the use of embryonic stem cells or animal products.
keywords:N/A
$76.8M
Total Funding
N/A
Number of Employees
$6M
Revenue (est)
N/A
Employee Growth %
N/A
Valuation
N/A
Accelerator
Histogen News
Histogen Inc (HSTO) stock is lower by -65.09% over the last 12 months, and the average rating from Wall Street analysts is a Strong Buy.
Two Sigma Securities LLC lifted its stake in Histogen by 124.7% during the third quarter. Two Sigma Securities LLC now owns 52,289 shares of the...
Histogen, which received a Nasdaq warning in August related its low bid price, expects the reverse split would help it meet Nasdaq requirements...
Other Companies in San Diego
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $18M | 0 | N/A | $168.6M |
#2 | $8.4M | 0 | N/A | N/A |
#3 | $11.7M | 0 | N/A | $4.4M |
#4 | $1.7M | 0 | N/A | N/A |
#5 | $18.3M | 0 | N/A | $79M |